Upper and lower system nasolacrimal duct stenosis secondary to paclitaxel

Ophthalmic Plastic and Reconstructive Surgery

Volumn 23, Issue 2, 2007, Pages 170-171

  McCartney, Emily ^a   Valluri, Shailaja ^b   Rushing, Dan ^b   Burgett, Richard ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PACLITAXEL;

AGED; ANGIOSARCOMA; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CASE REPORT; DISEASE SEVERITY; EPIPHORA; EYELID RECONSTRUCTION; HEAD AND NECK CARCINOMA; HUMAN; LACRIMAL DUCT OCCLUSION; MALE; PRIORITY JOURNAL; STENT; TREATMENT OUTCOME;

AGED; COMBINED MODALITY THERAPY; HEAD AND NECK NEOPLASMS; HEMANGIOSARCOMA; HUMANS; LACRIMAL DUCT OBSTRUCTION; MALE; NASOLACRIMAL DUCT; PACLITAXEL; TUBULIN MODULATORS;

EID: 34247098796     PISSN: 07409303     EISSN: None     Source Type: Journal    
DOI: 10.1097/IOP.0b013e318032e908     Document Type: Article

References (5)

1. Esmaeli B, Hortobagyi GN. Canalicular stenosis as the underlying mechanism for epiphora in patients receiving weekly docetaxel. Oncologist 2001;6:551-2.
2. Esmaeli B, Valero V, Ahmadi MA, et al. Canalicular stenosis secondary to docetaxel (Taxotere): a newly recognized side effect. Ophthalmology 2001;108:994-5.
3. Esmaeli B, Burnstine MA, Ahmadi MA, et al. Docetaxel-induced histiologic changes in the lacrimal sac and the nasal mucosa. Ophthalmic Plast Reconstr Surg 2003;19:305-8.
4. Skolnick CA, Doughman DJ. Erosive conjunctivitis and punctal stenosis secondary to docetaxel (Taxotere). Eye Contact Lens 2003;29:134-5.
5. Esmaeli B, Hortobagyi G, Esteva F, et al. Canalicular stenosis secondary to weekly docetaxel: a potentially preventable side effect. Ann Oncol 2002;13:218-21.